Literature DB >> 3930074

IFN-gamma-induced production of monocyte cytotoxic factor.

O Kildahl-Andersen, T Espevik, J Nissen-Meyer.   

Abstract

The effect of activating human monocytes in vitro with recombinant Interferon-gamma (IFN-gamma) and lymphokines on monocyte-mediated cytotoxicity and on the production of cytotoxic protein factor(s) (CF), has been investigated. Lymphokines and IFN-gamma enhanced both cytotoxicity and CF production in a dose-dependent manner. A monoclonal antibody against human IFN-gamma abrogated the lymphokine-induced cytotoxic activity and CF production completely, indicating that the actual monocyte-activating factor in the lymphokine supernatant was IFN-gamma. At concentrations of 10(3)-10(4) U/ml, IFN-gamma induced an enhanced release of CF from the monocytes. However, IFN-gamma at concentrations (less than 100 U/ml) present in our lymphokine preparation was not sufficient to induce enhanced CF release. Since IFN-gamma at concentrations less than 100 U/ml activated monocytes for cytotoxicity, CF as an extracellular factor in the supernatant does not appear to be essential for monocyte-mediated cytotoxicity. However, using neutralizing antiserum raised against purified CF, indirect immunofluorescence microscopy revealed that IFN-gamma induced a marked accumulation of CF on the monocyte membrane. Taken together, the data shows that IFN-gamma is both necessary and sufficient at concentrations less than 100 U/ml for inducing monocyte-mediated cytotoxicity and production of CF as a membrane-associated component, but not as a released factor, suggesting that CF may function as a membrane-associated cytotoxin in monocyte-mediated cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3930074     DOI: 10.1016/0008-8749(85)90326-0

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  9 in total

1.  Effect of interferon-gamma priming on the activation of murine peritoneal macrophages to tumouricidal state by cisplatin, IL-1, and tumour necrosis factor (TNF): production of IL-1 and TNF.

Authors:  A Sodhi; R K Singh; S M Singh
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

2.  The role of monocyte cytotoxic factor in monocyte-mediated lysis of tumour cells.

Authors:  T Espevik; O Kildahl-Andersen; J Nissen-Meyer
Journal:  Immunology       Date:  1986-02       Impact factor: 7.397

3.  Optimal induction of tumor necrosis factor production in human monocytes requires complete S-form lipopolysaccharide.

Authors:  D N Männel; W Falk
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

4.  WEHI 164 sarcoma cells rendered resistant to monocyte-released cytotoxin are also resistant to monocyte-induced cytolysis.

Authors:  O Kildahl-Andersen; R Austgulen; J Nissen-Meyer
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

5.  GM-CSF and IL-2 induce specific cellular immunity and provide protection against Epstein-Barr virus lymphoproliferative disorder.

Authors:  R A Baiocchi; J S Ward; L Carrodeguas; C F Eisenbeis; R Peng; S Roychowdhury; S Vourganti; T Sekula; M O'Brien; M Moeschberger; M A Caligiuri
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

6.  Destruction of tumor cells by monokines released from activated human blood monocytes: evidence for parallel and additive effects of IL-1 and TNF.

Authors:  Y Ichinose; J Y Tsao; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

7.  Tumor necrosis factor: recent advances.

Authors:  R Munker; H P Koeffler
Journal:  Klin Wochenschr       Date:  1987-04-15

8.  Tumour necrosis factor-like activity on paraformaldehyde-fixed monocyte monolayers.

Authors:  T Espevik; J Nissen-Meyer
Journal:  Immunology       Date:  1987-08       Impact factor: 7.397

9.  Induction of tumor necrosis factor by Legionella pneumophila.

Authors:  D K Blanchard; J Y Djeu; T W Klein; H Friedman; W E Stewart
Journal:  Infect Immun       Date:  1987-02       Impact factor: 3.441

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.